Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide hormone with roles in immune regulation, appetite control, and inflammation. KPV is a tripeptide fragment derived from the C-terminal end of alpha-MSH, and preclinical research demonstrates that this small peptide retains significant anti-inflammatory activity despite lacking the full-length hormone structure. This guide explains the mechanisms and research context for KPV and melanocortin signaling in laboratory studies.
Alpha-MSH is a neuropeptide with the sequence: Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val (13 residues). It is processed from a larger precursor (POMC) and acts as a hormone in multiple physiological systems: the brain, immune cells, and peripheral tissues. In the context of inflammation, alpha-MSH signals through melanocortin receptors (especially MC3R and MC5R) to suppress pro-inflammatory cytokine production and modulate immune responses.
KPV is the tripeptide corresponding to residues 11–13 of alpha-MSH: Lysine-Proline-Valine. Despite being only 3 amino acids, KPV exhibits significant anti-inflammatory activity in animal and cell-culture models. This fragment lacks the pigmentary activity associated with the full-length alpha-MSH hormone—KPV does not activate melanin synthesis in melanocytes—but retains strong immunoregulatory effects.
NF-κB and MAP-kinase modulation: Preclinical studies show that KPV reduces pro-inflammatory signaling by suppressing nuclear factor-kappa B (NF-κB) activation and extracellular signal-regulated kinase (ERK) phosphorylation. These pathways are central to inflammatory cytokine production in immune cells.
Receptor-independent intracellular mechanism: Interestingly, KPV's anti-inflammatory effects occur even in cell types where classical melanocortin receptors are absent or blocked, suggesting a substantially receptor-independent pathway. One characterized mechanism is cellular uptake via the peptide transporter PepT1, followed by intracellular modulation of inflammatory signaling cascades.
Cytokine suppression: Animal studies document that KPV reduces pro-inflammatory cytokine output (TNF-α, IL-6, IL-8) in intestinal and epithelial models, while having minimal effects on baseline or anti-inflammatory signaling.
The strongest preclinical evidence for KPV comes from inflammatory bowel disease (IBD) models in mice. Studies using experimental colitis demonstrate that KPV reduces intestinal inflammation, mucosal damage, and pro-inflammatory signaling compared to vehicle controls. The effect is consistent with KPV functioning as a dampener of the immune response rather than a direct wound-healing agent.
KPV has also been investigated in other inflammatory contexts—epithelial barrier dysfunction, acute immune responses, and systemic inflammation—with results generally supporting a role in immune-cell-mediated inflammation reduction.
KPV was initially placed on the FDA's Category 2 restricted list for 503A pharmacy compounding in 2023, removed in April 2026, and then placed under FDA advisory review on July 23, 2026. It has no recognized therapeutic drug class and no approved use in any indication. All current evidence is preclinical—animal models and cell culture—with limited human data.
Animal-to-human translation: IBD in mice is not identical to human IBD. Preclinical anti-inflammatory effects do not automatically translate to clinical efficacy in humans, and human pharmacokinetics of a peptide may differ substantially from rodent models.
Dose and route questions: Most preclinical KPV research uses intraperitoneal or intravenous administration in mice. The optimal dose, route, and formulation for human use (if any) remain unstudied.
Absence of human trials: As of 2026, no completed human clinical trials establish safety or efficacy of KPV for any condition.
Researchers investigating melanocortin signaling, immune modulation, or inflammatory pathways use KPV as a tool compound in cell and animal models. Its small size and cell-penetrating properties make it valuable for mechanistic studies of immune signaling. Universe Peptide supplies KPV with full analytical documentation for research use:
Browse KPV and research peptides
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.